Sullivan, Bruyette, Speros & Blaney’s NeoGenomics NEO Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$333K	Sell	6,910 -1,503	-18%	-$78.2K	0.01%	226
2020 Q4	$453K	Hold	8,413	–	–	0.02%	176
2020 Q3	$310K	Hold	8,413	–	–	0.02%	195
2020 Q2	$261K	Hold	8,413	–	–	0.02%	199
2020 Q1	$232K	Hold	8,413	–	–	0.02%	191
2019 Q4	$246K	Hold	8,413	–	–	0.01%	218
2019 Q3	$161K	Buy	+8,413	New	+$197K	0.01%	272

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

KFO

Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's NEO Position: Q1 2021 in Review

Sullivan, Bruyette, Speros & Blaney reduced its NeoGenomics (NEO) stake by 18% in Q1 2021, selling an estimated $78.2K and leaving 6,910 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #226.

Sullivan, Bruyette, Speros & Blaney first reported a position in NEO in Q3 2019 and has held it in 7 quarters since. The position peaked at $453K in Q4 2020. 332 funds tracked by Wall St. Rank hold NEO as of Q1 2021.

Sullivan, Bruyette, Speros & Blaney held 6,910 shares of NeoGenomics worth $333K as of Q1 2021.
Sullivan, Bruyette, Speros & Blaney sold 1,503 NeoGenomics shares in Q1 2021, an estimated $78.2K.
NeoGenomics made up 0.01% of Sullivan, Bruyette, Speros & Blaney's portfolio in Q1 2021, its #226 holding.
Sullivan, Bruyette, Speros & Blaney first reported a position in NeoGenomics in Q3 2019 and has held it in 7 quarters since.
Sullivan, Bruyette, Speros & Blaney's NeoGenomics position peaked at $453K in Q4 2020.
332 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2021.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q1 2021, filed 10 May 2021.